$895 Thousand is the total value of Bain Capital Life Sciences Investors, LLC's 33 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 71.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | NUVALENT INC | $106,531 | -99.8% | 3,577,267 | +4.4% | 11.90% | +49.7% | |
| New | NEWAMSTERDAM PHARMA COMPANYordinary shares | $90,470 | – | 8,300,000 | +100.0% | 10.11% | – | |
| NTRA | New | NATERA INC | $56,238 | – | 1,400,000 | +100.0% | 6.28% | – |
| CARA | Buy | CARA THERAPEUTICS INC | $28,955 | -99.9% | 2,696,030 | +1.8% | 3.24% | +9.4% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $25,796 | -99.9% | 2,364,410 | +4.6% | 2.88% | +26.7% |
| ANNX | Buy | ANNEXON INC | $25,264 | -99.9% | 4,886,616 | +35.7% | 2.82% | +6.2% |
| CTIC | New | CTI BIOPHARMA CORP | $22,702 | – | 3,777,308 | +100.0% | 2.54% | – |
| New | SOLID BIOSCIENCES INC | $16,842 | – | 3,130,422 | +100.0% | 1.88% | – | |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $12,117 | -99.9% | 12,202,510 | +91.0% | 1.35% | +3.8% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $11,166 | -99.9% | 701,402 | +14.9% | 1.25% | +4.7% |
| Buy | SYROS PHARMACEUTICALS INC | $7,628 | -99.9% | 2,124,694 | +96.3% | 0.85% | +2.4% | |
| New | NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $86 | – | 100,000 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
- BCLS II Investco (GP), LLC #6
- BCLS II Investco, LP #7
- Bain Capital Life Sciences III General Partner, LLC #8
- Bain Capital Life Sciences Fund III, L.P. #9
- Bain Capital Life Sciences Opportunities III GP, LLC #10
- Bain Capital Life Sciences Opportunities III, LP #11
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.